Tags

Type your tag names separated by a space and hit enter

Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine.
Pediatrics 2009; 123(5):1412-20Ped

Abstract

This statement updates and replaces the 2007 American Academy of Pediatrics statement for prevention of rotavirus gastroenteritis. In February 2006, a live oral human-bovine reassortant rotavirus vaccine (RV5 [RotaTeq]) was licensed as a 3-dose series for use in infants in the United States. The American Academy of Pediatrics recommended routine use of RV5 in infants in the United States. In April 2008, a live, oral, human attenuated rotavirus vaccine (RV1 [Rotarix]) was licensed as a 2-dose series for use in infants in the United States. The American Academy of Pediatrics recommends routine immunization of infants in the United States with rotavirus vaccine. The American Academy of Pediatrics does not express a preference for either RV5 or RV1. RV5 is to be administered orally in a 3-dose series with doses administered at 2, 4, and 6 months of age; RV1 is to be administered orally in a 2-dose series with doses administered at 2 and 4 months of age. The first dose of rotavirus vaccine should be administered from 6 weeks through 14 weeks, 6 days of age. The minimum interval between doses of rotavirus vaccine is 4 weeks. All doses should be administered by 8 months, 0 days of age. Recommendations in this statement also address the maximum ages for doses, contraindications, precautions, and special situations for administration of rotavirus vaccine.

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Practice Guideline

Language

eng

PubMed ID

19332437

Citation

Committee on Infectious Diseases, and American Academy of Pediatrics. "Prevention of Rotavirus Disease: Updated Guidelines for Use of Rotavirus Vaccine." Pediatrics, vol. 123, no. 5, 2009, pp. 1412-20.
Committee on Infectious Diseases, American Academy of Pediatrics. Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine. Pediatrics. 2009;123(5):1412-20.
Committee on Infectious Diseases. (2009). Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine. Pediatrics, 123(5), pp. 1412-20. doi:10.1542/peds.2009-0466.
Committee on Infectious Diseases, American Academy of Pediatrics. Prevention of Rotavirus Disease: Updated Guidelines for Use of Rotavirus Vaccine. Pediatrics. 2009;123(5):1412-20. PubMed PMID: 19332437.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine. AU - ,, AU - ,, Y1 - 2009/03/30/ PY - 2009/4/1/entrez PY - 2009/4/1/pubmed PY - 2009/5/27/medline SP - 1412 EP - 20 JF - Pediatrics JO - Pediatrics VL - 123 IS - 5 N2 - This statement updates and replaces the 2007 American Academy of Pediatrics statement for prevention of rotavirus gastroenteritis. In February 2006, a live oral human-bovine reassortant rotavirus vaccine (RV5 [RotaTeq]) was licensed as a 3-dose series for use in infants in the United States. The American Academy of Pediatrics recommended routine use of RV5 in infants in the United States. In April 2008, a live, oral, human attenuated rotavirus vaccine (RV1 [Rotarix]) was licensed as a 2-dose series for use in infants in the United States. The American Academy of Pediatrics recommends routine immunization of infants in the United States with rotavirus vaccine. The American Academy of Pediatrics does not express a preference for either RV5 or RV1. RV5 is to be administered orally in a 3-dose series with doses administered at 2, 4, and 6 months of age; RV1 is to be administered orally in a 2-dose series with doses administered at 2 and 4 months of age. The first dose of rotavirus vaccine should be administered from 6 weeks through 14 weeks, 6 days of age. The minimum interval between doses of rotavirus vaccine is 4 weeks. All doses should be administered by 8 months, 0 days of age. Recommendations in this statement also address the maximum ages for doses, contraindications, precautions, and special situations for administration of rotavirus vaccine. SN - 1098-4275 UR - https://www.unboundmedicine.com/medline/citation/19332437/Prevention_of_rotavirus_disease:_updated_guidelines_for_use_of_rotavirus_vaccine_ L2 - http://pediatrics.aappublications.org/cgi/pmidlookup?view=long&pmid=19332437 DB - PRIME DP - Unbound Medicine ER -